公开(公告)号：WO2004014876A1

公开(公告)日：2004-02-19

申请号：PCT/US2003/024474

申请日：2003-08-05

Applicant: ABBOTT LABORATORIES

Inventor： LI, Goaquan ,  LI, Qun ,  LI, Tongmei ,  LIN, Nan-Horng ,  MANTEI, Robert, A. ,  SHAM, Hing, L. ,  WANG, Gary, T.

IPC: C07D241/46

CPC classification number: C07D241/20

Abstract: Compounds having the formula are useful for inhibiting protein kinases. Also disclosed are methods of making thecompounds, compositions containing the compounds, and methods of treatment using the compounds.

Abstract translation: 具有该式的化合物可用于抑制蛋白激酶。 还公开了制备化合物的方法，含有化合物的组合物和使用该化合物的处理方法。

公开(公告)号：WO1997046554A1

公开(公告)日：1997-12-11

申请号：PCT/US1997009167

申请日：1997-06-04

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  LIN, Nan-Horng ,  HE, Yun ,  HOLLADAY, Mark, W. ,  RYTHER, Keith ,  LI, Yihong ,  BAI, Hao

IPC: C07D401/12

CPC classification number: C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14

Abstract: Novel 3-pyridyloxymethyl heterocyclic ether compounds of formula (I) or the pharmaceutically-acceptable salts or prodrugs thereof are selective and potent ligands at neuronal nicotinic cholinergic channel receptors, and are effective in controlling synaptic transmission. Key intermediates and processes using this key intermediates to produce compounds of formula (I) with the variables defined in the specification are also described.

Abstract translation: 式（I）的新型3-吡啶氧基甲基杂环醚化合物或其药学上可接受的盐或前药是神经元烟碱胆碱能通道受体的选择性和有效配体，并且有效控制突触传递。 还描述了使用这种关键中间体用式（I）化合物与说明书中定义的变量的关键中间体和方法。

公开(公告)号：WO2004076424A1

公开(公告)日：2004-09-10

申请号：PCT/US2004/005728

申请日：2004-02-26

Applicant: ABBOTT LABORATORIES

Inventor： HASVOLD, Lisa, A. ,  HEXAMER, Laura ,  LI, Gaoquan ,  LIN, Nan-Horng ,  SHAM, Hing ,  SOWIN, Tom ,  SULLIVAN, Gerard, M. ,  WANG, Le ,  XIA, Ping Xia

IPC: C07D243/38

CPC classification number: C07D243/38 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/12 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/06 ,  C07D413/10 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D491/10

Abstract: Compounds having the formula (I) are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Abstract translation: 具有式（I）的化合物可用于抑制蛋白激酶。 还公开了制备化合物，含有化合物的组合物和使用该化合物的处理方法的方法。

公开(公告)号：WO2003051838A3

公开(公告)日：2003-06-26

申请号：PCT/US2002/039641

申请日：2002-12-12

Applicant: ABBOTT LABORATORIES

Inventor： LIN, Nan-Horng ,  SHAM, Hing, L. ,  XIA, Ping

IPC: C07D403/06

Abstract: Compounds having the formula (I) or therapeutically acceptable salts thereof, are protein kinase inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of diseases using the compounds are disclosed.

公开(公告)号：WO1995007277A1

公开(公告)日：1995-03-16

申请号：PCT/US1994009734

申请日：1994-08-30

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  LIN, Nan-Horng ,  HE, Yun ,  ELLIOTT, Richard, L. ,  CHORGHADE, Mukund, S. ,  WITTENBERGER, Steven, J. ,  BUNNELLE, William, H. ,  NARAYANAN, Bikshandar, A. ,  SINGAM, Pulla, R. ,  ESCH, Thomas, K., J. ,  BEER, Dieter, O. ,  WITZIG, Christian, C. ,  HERZIG, Thomas, C. ,  RAO, Alla, V., Rama

IPC: C07D413/04

CPC classification number: C07D413/04

Abstract: A novel process for preparing enantiomerically-pure 3-methyl-5-(1-(C1-C3-alkyl)-2-pyrrolidinyl)isoxazole in high yield, wherein a protected pyrrolidine or 2-oxo-pyrrolidine starting material is reacted with a suitable organic anion and a resulting beta-keto oxime intermediate is cyclized and dehydrated, as well as intermediates useful in the preparation thereof.

Abstract translation: 以高产率制备对映异构纯的3-甲基-5-（1-（C 1 -C 3 - 烷基）-2-吡咯烷基）异恶唑的新方法，其中将受保护的吡咯烷或2-氧代 - 吡咯烷起始原料与 合适的有机阴离子和所得的β-酮肟中间体被环化和脱水，以及可用于其制备的中间体。

公开(公告)号：WO1994008992A1

公开(公告)日：1994-04-28

申请号：PCT/US1993009662

申请日：1993-10-08

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  ABREO, Melwyn, A. ,  GUNN, David, E. ,  LIN, Nan-Horng ,  ELLIOTT, Richard, L. ,  GARVEY, David, S. ,  LEBOLD, Suzanne, A. ,  WASICAK, James, T.

IPC: C07D401/12

CPC classification number: C07D401/12 ,  C07D403/12 ,  C07D417/12

Abstract: Novel heterocyclic ether compounds of formula (I), wherein A, B and R are specifically defined, or pharmaceutically-acceptable salts or prodrugs thereof, which are selective and potent ligands at cholinergic channel receptors, useful in the treatment of cognitive, neurological and mental disorders characterized by decreased cholinergic function.

Abstract translation: 具体定义的其中A，B和R 2的式（I）的新型杂环醚化合物或其药学上可接受的盐或前药，其是胆碱能通道受体的选择性和有效配体，可用于治疗认知， 以胆碱能功能下降为特征的神经和精神障碍。

公开(公告)号：WO2005047294A1

公开(公告)日：2005-05-26

申请号：PCT/US2004/036582

申请日：2004-11-03

Applicant: ABBOTT LABORATORIES ,  TAO, Zhi-Fu ,  LIN, Nan-Horng ,  WANG, Le ,  SOWIN, Thomas, J. ,  SULLIVAN, Gerard M. ,  TONG, Yunsong ,  PRZYTULINSKA, Magdalenna ,  LI, Gaoquan

Inventor： TAO, Zhi-Fu ,  LIN, Nan-Horng ,  WANG, Le ,  SOWIN, Thomas, J. ,  SULLIVAN, Gerard M. ,  TONG, Yunsong ,  PRZYTULINSKA, Magdalenna ,  LI, Gaoquan

IPC: C07D498/08

CPC classification number: C07D498/08 ,  C07D498/18

Abstract: Compounds having the formula (I) are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds

Abstract translation: 具有式（I）的化合物可用于抑制蛋白激酶。 还公开了制备化合物，含有化合物的组合物和使用该化合物的处理方法的方法

公开(公告)号：WO2004080973A1

公开(公告)日：2004-09-23

申请号：PCT/US2004/006921

申请日：2004-03-04

Applicant: ABBOTT LABORATORIES

Inventor： TONG, Yunsung ,  CLAIBORNE, Akiyo, K. ,  LI, Gaoquan ,  LIN, Nan-Horng ,  SHAM, Hing ,  TAO, Zhi-Fu ,  SOWIN, Tom

IPC: C07D231/54

CPC classification number: C07D249/08 ,  C07D231/12 ,  C07D231/54 ,  C07D233/56 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14

Abstract: Compounds having the formula (I) (I), are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Abstract translation: 具有式（I）（I）的化合物可用于抑制蛋白激酶。 还公开了制备化合物，含有化合物的组合物和使用该化合物的处理方法的方法。

公开(公告)号：WO2002074747A1

公开(公告)日：2002-09-26

申请号：PCT/US2001/043168

申请日：2001-11-30

Applicant: ABBOTT LABORATORIES

Inventor： CLAIBORNE, Akiyo, K. ,  GWALTNEY, Stephen, L, II ,  HASVOLD, Lisa, A. ,  LI, Qun ,  LI, Tomgmei ,  LIN, Nan-Horng ,  MANTEI, Robert, A. ,  ROCKWAY, Todd, W. ,  SHAM, Hing, L. ,  SULLIVAN, Gerard, M. ,  TONG, Yunsong ,  WANG, Gary, T. ,  WANG, Le ,  WANG, Xilu ,  WANG, Weibo

IPC: C07D233/64

CPC classification number: C07D233/64 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12

Abstract: Substituted imidazoles and thiazoles having formula (I), are useful for inhibiting farnesyltransferase. Also disclosed are farnesyltransferase-inhibiting compositions and methods of inhibiting farnesyltransferase in a patient.

Abstract translation: 具有式（I）的取代的咪唑和噻唑可用于抑制法呢基转移酶。 还公开了法呢基转移酶抑制组合物和在患者体内抑制法尼基转移酶的方法。

公开(公告)号：WO1998025920A1

公开(公告)日：1998-06-18

申请号：PCT/US1997022811

申请日：1997-12-10

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  HOLLADAY, Mark, W. ,  ARNERIC, Stephen, P. ,  BAI, Hao ,  DART, Michael, J. ,  LIN, Nan-Horng ,  LYNCH, John, K. ,  OR, Yat, Sun ,  RYTHER, Keith, B. ,  SULLIVAN, James, P. ,  WASICAK, James, T. ,  EHRLICH, Paul, P.

IPC: C07D401/12

CPC classification number: C07D401/12 ,  A61K31/4427 ,  A61K31/485 ,  C07D205/04 ,  Y02P20/55 ,  A61K2300/00

Abstract: The present invention relates to a method of controlling pain in mammals, including humans, comprising administering to a mammal or patient in need of treatment thereof selected compounds of formula (I) or a pharmaceutically acceptable salt thereof. The invention further relates to selected (R) and (S) compounds of formula (I) which are useful as analgesics as well as neuronal cell death preventors and anti-inflammatories.

Abstract translation: 本发明涉及一种控制包括人在内的哺乳动物疼痛的方法，包括向需要治疗的哺乳动物或患者施用选择的式（I）化合物或其药学上可接受的盐。 本发明进一步涉及可用作止痛剂以及神经元细胞死亡预防剂和抗炎剂的式（I）的选择的（R）和（S）化合物。